Hallucinogens Q&A

For a drug to be addictive it has to activate the pleasure system of the brain. LSD, peyote (mescaline) and psilocybin seen in "magic mushrooms" magnify anything and everything that is going on the brain and around the user. If the drugs are used in pleasurable situations, the pleasure is magnified. However, if something bad or upsetting is going on around users of psychedelic drugs, the bad feelings are very much magnified making for a bad trip. Addicting drugs overstimulate the pleasure part of the brain, but psychedelic drugs magnify what is going in and around the user.

The ability of some mushrooms to make user high was probably discovered by accident. Mushrooms have been used for many hundreds of years, especially as part of religious and spiritual experiences.

Lysergic acid, a product of mold that grows on rye wheat.

LSD is not an addictive drug; it works by turning off the natural filters in the brain that limit the amount of stimulation reaching consciousness. It isn’t a good recreational drug because it is very strong and hard to control the high. It may well have a role in treating mental illness, like depression and PTSD.

No. Even after tripping, including a bad trip, the negative effects dissipate. There are no lasting effects. There are some people who appear to be headed in the direction of a psychotic disorder (schizophrenia, Bipolar disease) who become psychotic after acid, and the consensus is that the acid trip brought out symptoms of an impending disorder.

No. Even after tripping, including a bad trip, the negative effects dissipate. There are no lasting effects. There are some people who appear to be headed in the direction of a psychotic disorder (schizophrenia, Bipolar disease) who become psychotic after acid, and the consensus is that the acid trip brought out symptoms of an impending disorder.

We still do not fully understand all of the long-term effects, especially in adolescents because the brain is still developing into the mid-20s. Some people report no lasting problems, while others can experience anxiety, mood changes, attention difficulties, or worsening mental health vulnerabilities. There is also concern that psychedelics may increase risk in people who are already vulnerable to conditions like psychosis or severe anxiety.

Researchers are studying psychedelics very carefully in controlled medical settings because they may help some people with severe depression, PTSD, anxiety, or addiction when combined with therapy. These substances appear to affect serotonin systems and may temporarily change how people process emotions, memories, and self-reflection. That is very different from unsupervised recreational use.

Psilocybin mushrooms (the active compound being psilocybin, which converts to psilocin in the body) produce effects including altered perception of time and space, visual and auditory hallucinations, synesthesia (such as "seeing" sounds), intensified emotions, a sense of deep meaning or connectedness, and occasionally anxiety, paranoia, or a "bad trip." Physical symptoms include dilated pupils, increased heart rate, nausea, and yawning. Effects typically begin 30–60 minutes after ingestion and last 4–6 hours. Regarding legal dose: psilocybin mushrooms remain classified as a Schedule I controlled substance at the federal level in the U.S., meaning there is no federally recognized legal dose for recreational use. Oregon and Colorado have legalized regulated therapeutic use for adults. In research and clinical settings, therapeutic doses typically range from 10–30 mg of psilocybin, administered in a highly controlled environment with professional support.

"Dangerous" depends on context and individual factors. From a toxicity standpoint, psilocybin mushrooms have one of the lowest physiological toxicity profiles of any psychoactive substance — the lethal dose for a human is so high as to be practically impossible to reach through normal use. However, "not very toxic" is not the same as "safe." The risks of mushrooms are primarily psychological rather than physiological: a "bad trip" can involve intense paranoia, panic, and terrifying experiences that can cause lasting psychological distress. The risk of HPPD (persistent visual disturbances) is real, though relatively uncommon. For individuals with a personal or family history of psychosis, schizophrenia, or bipolar disorder, psilocybin can be genuinely dangerous; it can trigger or accelerate the onset of these conditions. There is also the practical danger of misidentification: wild mushroom poisoning from accidentally consuming toxic species while foraging is a genuine medical emergency. For an adolescent with a still-developing brain, the precautionary risk-benefit calculation is clearly unfavorable.